Terns Pharmaceuticals Receives Fast Track Designation for TERN-201 as a Treatment for NASH

This article was originally published here

Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings

The post Terns Pharmaceuticals Receives Fast Track Designation for TERN-201 as a Treatment for NASH appeared first on Pharmaceutical Business review.